- Conditions
- Influenza, Human, Pregnancy, Birth Defect
- Interventions
- Flucelvax Trivalent Influenza Vaccine, Flucelvax Quadrivalent Influenza Vaccine
- Biological
- Lead sponsor
- Seqirus
- Industry
- Eligibility
- Female only
- Enrollment
- 692 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1705–1728
of 10,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- Inhaled Nitric Oxide (iNO), Nitrogen (placebo)
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- Up to 72 Hours
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Diego, California • Aurora, Colorado + 3 more
- Conditions
- Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
- Interventions
- Treatment with HydroPearl via radial access
- Device
- Lead sponsor
- Terumo Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 3 more
- Conditions
- Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- Peripheral Blood Stem Cell Transplantation
- Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Primary Hyperoxaluria Type 1 (PH1)
- Interventions
- Placebo, Lumasiran
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 5
- States / cities
- San Diego, California • Jacksonville, Florida • Rochester, Minnesota + 2 more
- Conditions
- Sickle Cell Disease
- Interventions
- IMR-687, Placebo
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 7
- States / cities
- Oakland, California • Farmington, Connecticut • Hollywood, Florida + 3 more
- Conditions
- Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II
- Interventions
- Not listed
- Lead sponsor
- Novartis
- Industry
- Eligibility
- Up to 14 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Prostate Cancer, Prostatic Neoplasms
- Interventions
- Panobinostat, Bicalutamide
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 4
- States / cities
- New Brunswick, New Jersey • Lake Success, New York • New York, New York + 1 more
- Conditions
- Sickle Cell Anemia, Retinopathy
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Kresge Eye Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Arrhythmia in Children, Congenital Heart Disease
- Interventions
- Provocative electrophysiology study
- Diagnostic Test
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Post-Mastectomy Breast Deformity (Disorder)
- Interventions
- Regenerative post mastectomy surgery
- Procedure
- Lead sponsor
- BioAesthetics
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Non-atopic Healthy Controls
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Rochester, New York • Portland, Oregon
- Conditions
- Atopic Dermatitis
- Interventions
- Abrocitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
- Conditions
- Cystic Fibrosis, Oxidative Stress, Inflammation
- Interventions
- finely ground flaxseed powder
- Dietary Supplement
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HSP, Hereditary Spastic Paraplegia, Hereditary Spastic Paraparesis, Hereditary Spastic Paraplegia Type 50, Hereditary Spastic Paraplegia Type 47, Hereditary Spastic Paraplegia Type 51, Hereditary Spastic Paraplegia Type 52, SPG47, AP4B1, Neurogenetic Disorders, Neurodevelopmental Conditions, Movement Disorders, Gene Therapy
- Interventions
- BFB-101 (AAV9-CBh-AP4B1)
- Biological
- Lead sponsor
- BlackfinBio Ltd
- Industry
- Eligibility
- 12 Months to 60 Months
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Congenital Heart Disease, Single-ventricle
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 10 Years to 60 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
- Interventions
- Deucrictibant, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • San Diego, California + 5 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab Pen
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Ficerafusp alfa, Pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- Bicara Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Fort Myers, Florida • Orlando, Florida • St. Petersburg, Florida + 4 more
- Conditions
- Huntington's Disease
- Interventions
- Creatine monohydrate
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 26 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Prader-Willi Syndrome
- Interventions
- NNZ-2591
- Drug
- Lead sponsor
- Neuren Pharmaceuticals Limited
- Industry
- Eligibility
- 4 Years to 12 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- San Diego, California • Atlanta, Georgia • Chevy Chase, Maryland + 1 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-118
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Macular Dystrophy, Corneal
- Interventions
- 4-Methylpyrazole, saline
- Drug · Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG), Mixed Hyperlipemia, Hypercholesterolaemia
- Interventions
- CTX310
- Drug
- Lead sponsor
- CRISPR Therapeutics AG
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Hialeah, Florida • Jacksonville, Florida • Orlando, Florida + 5 more